NCT02237183View on ClinicalTrials.gov

Iloprost in Preventing Lung Cancer in Former Smokers

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 5, 2015

Primary Completion Date

March 5, 2020

Study Completion Date

August 30, 2023

Conditions
Lung Carcinoma
Interventions
DRUG

Iloprost

Given via inhalation

OTHER

Placebo Administration

Given via inhalation

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (2)

80045

UCHealth University of Colorado Hospital, Aurora

80217-3364

University of Colorado, Denver

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02237183 - Iloprost in Preventing Lung Cancer in Former Smokers | Biotech Hunter | Biotech Hunter